Takeda, Equasym, Elvanse, Intuniv – Guidelines Portfolio

Takeda want to be perceived as a trusted partner for the treatment of ADHD in children and young people and become the market leader. They have a great product portfolio to match NICE guidelines and considerations and want to make HCPs aware of this. The purpose of the brief was to convey the importance of finding the most effective treatment option for CYP ADHD patients using negative and positive imagery and in a variety of channels. This was to be communicated to HCPs with young patients suffering with ADHD. Multiple materials were created including a guidelines portfolio.